Clinical Trial Update: Immune Responses to Two Dose Varivax +/- MMR-II [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing immune responses to two doses of Varivax with or without MMR-II in measles, mumps, rubella, and varicella was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella
• Varicella

Drugs mentioned

• MMR-II (Measles, Mumps, and Rubella vaccine)
• Varivax (varicella vaccine (live attenuated))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Measles, Mumps | Phase 1, Phase 2 | Status: TERMINATED